JAK1, Janus kinase 1, 3716

N. diseases: 239; N. variants: 41
Disease: Graft-vs-Host Disease ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.050 Biomarker disease BEFREE Itacitinib is a potent, selective JAK-1 inhibitor currently in phase 3 development for the treatment of acute and chronic graft-versus-host disease (GVHD) in combination with corticosteroids. 31282592 2019
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.050 Biomarker disease BEFREE Itacitinib is a JAK1-selective inhibitor in phase 3 development in graft-versus-host disease. 31821750 2019
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.050 Biomarker disease BEFREE Cytokine receptor associated kinases JAK1 and JAK2 are critical for inflammatory cytokine response in GvHD. 30453910 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.050 Biomarker disease BEFREE A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease. 28445193 2017
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.050 Biomarker disease BEFREE Inhibition of JAK1/2 or CIITA knockdown in DCs prevented miR-146a<sup>-/-</sup> DC-induced GVHD exacerbation. 28484267 2017